


In the Claims

Applicant has submitted a new complete claim set indicating marked up claims with insertions and deletions indicated by underlining and strikeouts, respectively.

1. (Original) A compound of formula (I)



or a salt thereof, or a solvate thereof,
wherein;

R₁ and R₂ each independently represents C₁₋₆alkoxy or halo;

R₃ and R₄ each independently represents hydrogen, C₁₋₆alkoxy, arylC₁₋₆alkoxy, hydroxy, carboxyC₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, dihydroxyC₁₋₆alkoxy, mono- and di-(C₁₋₆alkyl)aminoC₁₋₆alkoxy or aminoC₁₋₆alkoxy and;


R₅ represents -NR_sR_t wherein R_s and R_t each independently represent hydrogen, unsubstituted or substituted C₁₋₆alkyl, or unsubstituted or substituted heterocyclyl.

2. (Original) A compound according to claim 1 wherein R₁ and R₂ each independently represents methoxy or chloro.

3. (Previously presented) A compound according to claim 1 wherein R₁ is 5-chloro and R₂ is 6-chloro.

4. (Original) A compound according to claim 1 wherein R₃ is hydroxy, methoxy, ethoxy, propoxy, benzyloxy, carboxyethoxy, hydroxyethoxy, dihydroxypropoxy, dimethylaminoethoxy or aminopropoxy.


5. (Original) A compound according to claim 1 wherein R_4 is hydrogen or methoxy.
6. (Original) A compound according to claim 1 wherein R_5 or R_1 represent unsubstituted or substituted C_{1-6} alkyl, or unsubstituted or substituted heterocyclyl.
7. (Previously presented) A compound according to claim 1 wherein R_5 or R_1 represent 3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl or 3-[4-(2-pyrimidinyl)piperazin-1-yl]propyl.
8. (Original) A compound according to claim 1 wherein R_5 or R_1 represent an unsubstituted or substituted piperidinyl group.
9. (Previously presented) A compound according to claim 1 wherein R_5 or R_1 represent a 1,2,2,6,6-pentamethylpiperidin-4-yl group or a 2,2,6,6-tetramethylpiperidin-4-yl group.
10. (Original) A compound according to claim wherein R_1 is hydrogen.
11. (Currently amended) A compound of formula (IA) according to claim 1



wherein;

~~R₁, R₂, R₃, R₄, and R₅ are as defined in formula (I) of claim 1~~, R₅ is 3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl or 3-[4-(2-pyrimidinyl)piperazin-1-yl]propyl, and R₁ is hydrogen or a salt thereof or a solvate thereof.


12. (Currently amended) A compound of ~~formula (IB)~~ according to claim 1



wherein;

~~R₁, R₂, R₃, R₄, and R₅ are as defined in formula (I) of claim 1~~, R₅ is 3-pyridyl or 3-(6-methoxy)pyridyl, and R₁ is hydrogen or a salt thereof or a solvate thereof.


13. (Currently amended) A compound of ~~formula (IC)~~ according to claim 1



wherein;

~~R₂, R₄, and R₅ are as defined in formula (I) of claim 1~~, R₅ is 2,2,6,6-tetramethylpiperidin-4-yl, R_t is hydrogen, R₃ is 3-ethoxy, and R₁ is 5-chloro or 5-methoxy or a salt thereof or a solvate thereof.


14. (Currently amended) A compound ~~of formula (ID)~~ according to claim 1



wherein;

~~R₁, R₂, R₄, and R₅ are as defined in formula (I) of claim 1~~, R₅ is 2,2,6,6-tetramethylpiperidin-4-yl, R_t is hydrogen, R₃ is 2-methoxy, 3-methoxy, 3-ethoxy, 3-propoxy, 3-benzyloxy, 3-(2-carboxyethoxy), 3-(2-hydroxyethoxy), 3-(2,3-dihydroxypropoxy), 3-(2-dimethylaminoethoxy) or 3-(3-aminopropoxy) and 3-hydroxy and R₄ is 5-methoxy or hydrogen or a salt thereof or a solvate thereof.


15. (Currently amended) A compound ~~of formula (IE)~~ according to claim 1



wherein;

~~R₁, R₂, R₄, and R₅ are as defined in formula (I) of claim 1~~, R_s is 1,2,2,6,6-pentamethylpiperidin-4-yl, R_t is hydrogen, and R₃ is 2-methoxy or 3-ethoxy, and R₄ is 5-methoxy or hydrogen or a salt thereof or a solvate thereof.

16. (Currently amended) A compound ~~of formula (IF)~~ according to claim 1



wherein;


~~R₁, R₂, R₃, R₄, and R₅ are as defined in formula (I) of claim 1~~, R_s is 1-benzylpiperidin-4-yl, 1-(4-ethoxycarbonyl)butylpiperidin-4-yl, 1-(4-hydroxycarbonyl)butylpiperidin-4-yl and R_t is hydrogen or a salt thereof or a solvate thereof.

17. (Original) A compound selected from the list consisting of:

4-(5,6-dichloro-1H-indol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)-benzamide;
 4-(5,6-dichloro-1H-indol-2-yl)-3-benzyloxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)-benzamide;
 4-(5,6-dichloro-1H-indol-2-yl)-3-hydroxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)-benzamide;
 4-(5,6-dichloro-1H-indol-2-yl)-3-propoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzamide;
 4-(5,6-dichloro-1H-indol-2-yl)-N-[3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl]-3-methoxybenzamide;
 4-(5,6-dichloro-1H-indol-2-yl)-N-[3-[4-(2-pyrimidyl)piperazin-1-yl]propyl]-3-methoxybenzamide;

4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-methoxybenzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-3-ethoxybenzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(3-pyridyl)-3-ethoxybenzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(3-(6-methoxypyridyl))-3-ethoxybenzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(1-benzylpiperidin-4-yl)-3-ethoxybenzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-2,5-dimethoxybenzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,5-dimethoxybenzamide;
4-(5-methoxy-6-chloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-ethoxybenzamide;
4-(5,6-dichloro-1H-indol-2-yl)-3-methoxy-N-((1-ethoxycarbonylpentyl)piperidin-4-yl)-benzamide;
C I 4-(5,6-dichloro-1H-indol-2-yl)-3-methoxy-N-((carboxybutyl)piperidin-4-yl)benzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(hydroxycarbonylmethoxy)benzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(2-hydroxyethoxy)benzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(3-amino-propoxy)benzamide;
4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(2-dimethylaminoethoxy)benzamide, and;
4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(2,3-hydroxy-propoxy)benzamide.

18. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 or a salt thereof or a solvate thereof, which process comprises the amidation of a compound of formula (II)



wherein;

R_1' , R_2' , R_3' , and R_4' each respectively represent R_1 , R_2 , R_3 , and R_4 as defined in relation to formula (I) or a protected form thereof, with a compound of formula (III)



wherein;

R_s and R_t each represent R_s and R_t as defined in relation to formula (I) or a protected form thereof and thereafter, as necessary, carrying out one or more of the following steps:

- (i) converting one compound of formula (I) into another compound of formula (I);
- (ii) removing any protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

19. (Original) A method for the treatment and/or prophylaxis of diseases associated with over activity of osteoclasts in mammals which method comprises the administration of an effective non-toxic amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

20. (Original) A method for the treatment of osteoporosis and related osteopenic diseases in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

C 1 21. (Currently amended) A method for the treatment of tumours, ~~especially those related to renal cancer, melanoma, colon cancer, lung cancer and leukemia, viral conditions (for example those involving Semliki Forest, Vesicular Stomatitis, Newcastle Disease, Influenza A and B, HIV viruses), ulcers (for example chronic gastritis and peptic ulcer induced by Helicobacter pylori), autoimmune diseases, and transplantation, for the treatment and/or prevention of~~ hypercholesterolemic and atherosclerotic diseases, AIDS and Alzheimer's disease, angiogenic diseases, ~~such as rheumatoid arthritis, diabetic retinopathy, psoriasis and solid tumours,~~ in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula I ~~as defined in~~ according to claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

22-25. (Canceled)

26. (Original) A pharmaceutical composition comprising a compound of formula as defined in claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof and a pharmaceutically acceptable carrier therefor.

27-29. (Canceled)
